The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10322561" target="_blank" >RIV/00669806:_____/16:10322561 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/16:00090185 RIV/00216208:11140/16:10322561
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy
Popis výsledku v původním jazyce
Abstract. Backround: The prognostic and predictive value of KRAS mutation in non-small cell lung cancer (NSCLC) is not well established. The present study is aimed at an elucidation of a role of KRAS mutation in prediction of outcome of patients with advanced NSCLC receiving second or third line chemotherapy. Patients and Methods: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at 2nd or 3rd line therapy was retrospectively analyzed. Results: Progression-free survival (PFS) was not significantly different between KRAS mutated and KRAS wild-type patients. The results were the same even if we have taken into account the specific types of KRAS mutations. Overall survival (OS) was significatnly longer for KRAS wild-type vs. KRAS mutated patients (16.1 vs.7.2 months). We observed shorter OS for G12C KRAS mutation vs. other KRAS mutation group of patients (median OS 10.3 vs 6.4 months). Conclusion: We observed that presence of KRAS mutation (especially KRAS G12C mutation) correlated with adverse prognosis in patients treated with 2nd or 3rd line pemetrexed or docetaxel.
Název v anglickém jazyce
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy
Popis výsledku anglicky
Abstract. Backround: The prognostic and predictive value of KRAS mutation in non-small cell lung cancer (NSCLC) is not well established. The present study is aimed at an elucidation of a role of KRAS mutation in prediction of outcome of patients with advanced NSCLC receiving second or third line chemotherapy. Patients and Methods: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at 2nd or 3rd line therapy was retrospectively analyzed. Results: Progression-free survival (PFS) was not significantly different between KRAS mutated and KRAS wild-type patients. The results were the same even if we have taken into account the specific types of KRAS mutations. Overall survival (OS) was significatnly longer for KRAS wild-type vs. KRAS mutated patients (16.1 vs.7.2 months). We observed shorter OS for G12C KRAS mutation vs. other KRAS mutation group of patients (median OS 10.3 vs 6.4 months). Conclusion: We observed that presence of KRAS mutation (especially KRAS G12C mutation) correlated with adverse prognosis in patients treated with 2nd or 3rd line pemetrexed or docetaxel.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FC - Pneumologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Svazek periodika
36
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
6
Strana od-do
1077-1082
Kód UT WoS článku
000375444200033
EID výsledku v databázi Scopus
2-s2.0-84991721108